A Phase 2 Study of the JAK1/JA2 Inhibitor Ruxolitinib

Project: Research project

Project Details

Description

A Phase 2 Study of the JAK1/JA2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
StatusActive
Effective start/end date7/1/161/31/21

Funding

  • Children's Hospital of Philadelphia

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.